The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical tariffs given their “speculative” nature, its CFO told analysts.
The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical tariffs given their “speculative” nature, its CFO told analysts.
